4SCAR-CD44v6

4SCAR-CD44v6 is a fourth-generation chimeric antigen receptor (CAR) T cell therapy in which patient or donor T lymphocytes are genetically modified using a lentiviral vector to express a CAR targeting the CD44 variant domain 6 (CD44v6), an isoform of the cell surface adhesion molecule CD44. The engineered T cells are designed to recognize and eliminate cancer cells expressing CD44v6, which is implicated in tumorigenesis, invasion, and metastasis. This target is expressed in most squamous cell carcinomas and subsets of adenocarcinomas, melanoma, lymphoma, multiple myeloma, breast cancer, prostate cancer, and stomach cancer. The therapy aims to provide specific cytotoxicity against these cancers by redirecting the immune response toward malignant cells expressing the antigen[1][2][5][7]. The developer of this therapy is Shenzhen Geno-Immune Medical Institute.

Other names

CD44v6-specific CAR-T cellsCD-44v6-specific CAR-T cellsCD 44v6-specific CAR-T cellsCD44v6 CAR-T cell therapyCD-44v6 CAR-T cell therapyCD 44v6 CAR-T cell therapyCD44v6.CAR T cellsCD-44v6.CAR T cellsCD 44v6.CAR T cells